More Related Content
What's hot
What's hot (20)
Similar to Weekly Health Care News No.3 (2016-03-20)
Similar to Weekly Health Care News No.3 (2016-03-20) (20)
Recently uploaded
Recently uploaded (20)
Weekly Health Care News No.3 (2016-03-20)
- 1. Contact: Harald Schelenz Linkedin: https://de.linkedin.com/in/haraldschelenz Mail: hs.healthcarenews@gmail.com Xing: https://www.xing.com/profile/Harald_Schelenz page1 Focus on Europe Focus on North America Focus on Asia Pacific AstraZeneca and its R&D arm, MedImmune, disclosed that its investigational anti-CD19 monoclonal antibody, MEDI-551, was given Orphan Drug Status by the FDA. (marketexclusive.com) GlaxoSmithKline s CEO A dre Witty retires as chief executive in March 2017, after a career at the company spanning more than 30 years and a tumultuous near-decade as its chief. (wsj.com) Novartis’ heart-failure pill Entresto hits hurdles ith do tors’ pres riptio . The drug had so far $ million in sales, while $126 million were expected by industry analysts. (wsj.com) Novo Nordisk's hemophilia drug Novoeight infringed claims of a Baxter International Inc. patent, a U.S. International Trade Commission court ruled. (bna.com) Roche announced that the FDA has accepted the company's Biologics License Application (BLA) and granted Priority Review for atezolizumab. (fiercebiotech.com) Sanofi could pay privately held DiCE Molecules as much as $2.3 billion under a partnership deal that aims to find new oral medicines to replace injections for certain diseases. (reuters.com) Weekly News Wrap-Up: HEALTH CARE Industry No. 3 2016-03-20 Amgen AstraZeneca BioMarin Daiichi Sankyo Healthcare Eli Lilly Fisher & Paykel GlaxoSmithKline Johnson & Johnson Kyowa Hakko Kirin Novartis Novo Nordisk Pfizer SPOTLIGHT COMPANY NEWS Amgen s t o pate ts li ked to the o pa y’s re e tly appro ed holesterol-lowering drug have been declared valid by a jury. (wsj.com) BioMarin is going to yield news this month on its drug in phase III in phenylketonuria (PKU). The drug is a promising candidate to treat an as yet incurable condition. (marketexclusive.com) Eli Lilly changed the scientific goal of a closely at hed Phase Alzhei er’s trial of its sola ezu a drug i people ith ild Alzhei er’s de e tia. It ill o o ly ie og itio . (wsj.com) Johnson & Johnson and its DePuy unit were ordered to pay about $500 million to five plaintiffs who said they were injured by Pinnacle metal-on-metal hip implants. (reuters.com) Pfizer's Xalkori has won a new use in patients with rare variation of lung cancer. The FDA says Xalkori capsules are now approved for patients with the ROS-1 gene mutation. (usnews.com) Fisher & Paykel Healthcare was the 2015 Supreme Winner of ExportNZ's annual awards, generating 99 percent of its revenue from exports, while forecasting operating revenue of $800m. (stuff.co.nz) Daiichi Sankyo Healthcare found out in a survey that elderly people retaining their natural teeth prefer toothpastes preventing gum disease, alveolar pyorrhea and bad breath. (japantimes.co.jp) Kyowa Hakko Kirin will start the operations of drug product manufacturing facility from March 2016 in China. The project involves an investment of some 1 billion yen. (thepharmaletter.com)
- 2. Contact: Harald Schelenz Linkedin: https://de.linkedin.com/in/haraldschelenz Mail: hs.healthcarenews@gmail.com Xing: https://www.xing.com/profile/Harald_Schelenz page2 94% 96% 98% 100% 102% 2016-03-14 2016-03-15 2016-03-16 2016-03-17 2016-03-18 Europe North America Asia/Pacific Regional Comparison Focus on Europe Taking a closer look at the regional development of the biggest listed health care companies, there was an overall weekly decline of -3.4% on a global level, further increasing the loss of -16.1% on a yearly basis. Worst performance this week showed the North American region with -3.8%, followed by Europe with -2.94%. Both regions reach double digit negative development on a yearly basis. Weekly News Wrap-Up: HEALTH CARE Industry No. 3 2016-03-20 Actelion Coloplast Gerresheimer Hikma Pharmaceuticals Lonza Group Morphosys Orpea Roche Sanofi Stada SPOTLIGHT FINANCIAL MARKET NEWS Index closing price 1 week change 1 year change 1 week's high 1 week's low 1 year's high 1 year's low STOXX® Europe 600 Health Care 689.56 -2.94% -18.53% 719.14 686.64 879.13 654.95 STOXX® North America 600 Health Care 776.32 -3.82% -16.80% 811.48 758.75 966.34 730.68 STOXX® Asia/Pacific 600 Health Care 414.56 -1.74% -0.24% 427.22 412.33 446.92 349.32 STOXX® Global 1800 Health Care 684.53 -3.43% -16.14% 713.99 675.86 842.76 647.94 The strongest performer from Europe in the weekly performance ranking is Stada with an increase of +6.7% while its one year performance reaches +11.9%. Second is Hikma Pharmaceuticals with a value gain of +6.3% on a weekly basis though it shows a negative development of -25.2% on a yearly basis. top 5 companies closing price 1 week change 1 year change 1 week's high 1 week's low 1 year's high 1 year's low Stada 34.28 +6.69% +11.94% 34.28 32.21 37.37 28.07 Hikma Pharmaceuticals 23.31 +6.27% -25.21% 23.88 20.88 34.56 20.88 Morphosys 41.61 +4.36% -39.25% 43.35 39.82 76.96 33.82 Lonza Group 159.50 +3.03% +25.35% 148.11 141.71 151.00 111.63 Gerresheimer 68.27 +2.75% +31.43% 69.23 66.80 76.43 48.73 flop 5 companies closing price 1 week change 1 year change 1 week's high 1 week's low 1 year's high 1 year's low Actelion 119.88 -6.29% +9.58% 129.29 120.10 142.12 105.57 Roche 214.63 -4.79% -15.52% 228.74 212.51 279.90 212.50 Orpea 72.26 -4.55% +19.86% 76.60 70.81 76.72 58.21 Coloplast 65.48 -4.51% -7.90% 70.20 65.07 78.50 55.69 Sanofi 70.73 -4.36% -23.44% 75.36 70.84 101.00 66.50 Regarding this week’s low performers from Europe, the worst development experienced Actelion with a decrease of -6.3%, although its one year change still shows +9.6%. In second place is Roche with a loss of -4.8% on a weekly basis, further deteriorating its one year decline of -15.5%.